PB2351: TRIAL IN PROGRESS: A PHASE 2, MULTICENTRE STUDY OF BRENTUXIMAB VEDOTIN WITH CHEMOTHERAPY IN FRONTLINE TREATMENT OF CHINESE PATIENTS WITH CD30-POSITIVE PERIPHERAL T-CELL LYMPHOMAS

PB2351: TRIAL IN PROGRESS: A PHASE 2, MULTICENTRE STUDY OF BRENTUXIMAB VEDOTIN WITH CHEMOTHERAPY IN FRONTLINE TREATMENT OF CHINESE PATIENTS WITH CD30-POSITIVE PERIPHERAL T-CELL LYMPHOMAS

Bibliographic Details
Main Authors:	Yuqin Song, Helen Wu, Meng Ji, Wenhan Jiang, Cassie Dong, Jun Zhu
Format:	Article
Language:	English
Published:	Wiley 2023-08-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000976124.84505.49

Similar Items

Brentuximab vedotin in pediatric Hodgkin lymphoma
by: Shuvadeep Ganguly, et al.
Published: (2022-01-01)

Overall survival with brentuximab vedotin in advanced Hodgkin lymphoma
by: Shuvadeep Ganguly, et al.
Published: (2022-01-01)

Clinical Observation of 32 Cases of Malignant Lymphoma Treated with Brentuximab Vedotin Combined with Chemotherapy
by: CHAI Xiaofei, et al.
Published: (2023-03-01)

Evans Syndrome as a Possible Complication of Brentuximab Vedotin Therapy for Peripheral T Cell Lymphoma
by: Ruxandra Irimia, et al.
Published: (2023-03-01)

Brentuximab vedotin is the first target drug in the treatment of hodgkin lymphoma
by: G. S. Tumyan
Published: (2018-11-01)

Brentuximab vedotin use in pediatric anaplastic large cell lymphoma
by: Jennifer E. Agrusa, et al.
Published: (2023-05-01)

Safety of Concurrent Radiation Therapy With Brentuximab Vedotin in the Treatment of Lymphoma
by: Susan Y. Wu, MD, et al.
Published: (2023-11-01)

Testing sensitivity to cd30 targeting via brentuximab vedotin in multiple myeloma
by: E. La Spina, et al.
Published: (2020-09-01)

PB2351: ANXIETY AT THE HEMATOLOGIST
by: S. Trojan, et al.
Published: (2022-06-01)

PB2399: BRENTUXIMAB VEDOTIN IN TREATING CHINESE PATIENTS WITH LYMPHOMA:A MULTICENTER,REAL-WORLD STUDY
by: Xudong Zhang, et al.
Published: (2023-08-01)

SUCCESSFUL USE OF BRENTUXIMAB VEDOTIN IN THE TREATMENT OF PROGRESSIVE PERIPHERAL UNSPECIFIED T-CELL LYMPHOMA IN AN ELDERLY FEMALE PATIENT
by: L. G. Gorenkova, et al.
Published: (2017-06-01)

Improvement of Cutaneous Anaplastic Large Cell Lymphoma by Brentuximab Vedotin Monotherapy
by: Takashi Onaka, et al.
Published: (2018-05-01)

Cutaneous Anaplastic Large-Cell Lymphoma with Dramatic Response to Brentuximab Vedotin
by: Mustafa Şahin, et al.
Published: (2021-02-01)

Brentuximab vedotin treatment for mycosis fungoides with CD30+ large‐cell transformation in the early stage
by: Shujiro Hayashi, et al.
Published: (2023-12-01)

Sézary Syndrome with Nodal CD30-positive Manifestation Treated with Brentuximab Vedotin and Extracorporeal Photopheresis
by: Valeria Behle, et al.
Published: (2017-05-01)

TARGETED THERAPY WITH BRENTUXIMAB VEDOTIN IN RELAPSED AND REFRACTORY FORMS OF CLASSICAL HODGKIN LYMPHOMA
by: E. A. Demina
Published: (2017-11-01)

COST-EFFECTIVENESS ANALYSIS OF BRENTUXIMAB VEDOTIN IN ADULTS WITH RELAPSED OR REFRACTORY HODGKIN’S LYMPHOMA
by: G. R. Khachatryan, et al.
Published: (2016-04-01)

P1130: FRONTLINE BRENTUXIMAB VEDOTIN AND CHP (A+CHP) IN PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA WITH LESS THAN 10% CD30 EXPRESSION: INITIAL SAFETY AND EFFICACY RESULTS FROM THE PHASE 2 STUDY SGN35-032
by: Swaminathan Iyer, et al.
Published: (2023-08-01)

Brentuximab vedotin as a bridge to combination chemotherapy in gray zone lymphoma with severe liver impairment: a case report
by: Roshan Asrani, et al.
Published: (2024-01-01)

Brentuximab vedotin in treating Chinese patients with lymphoma: A multicenter, real‐world study
by: Xudong Zhang, et al.
Published: (2023-12-01)

Brentuximab vedotin resistance in classic Hodgkin's lymphoma and its therapeutic strategies: a review
by: Dayeeta Bera, et al.
Published: (2024-02-01)

Hodgkin’s Lymphoma after Autologous Stem-Cell Transplantation: Effective Consolidation with Brentuximab Vedotin
by: Adrian Schmidt
Published: (2020-11-01)

Brentuximab vedotin (Adcetris®) in therapy of system anaplastic large cell lymphoma. Case report
by: A. A. Semenova, et al.
Published: (2019-01-01)

Pharmacoeconomic analysis of therapy with brentuximab vedotin, nivolumab and pembrolizumab in patients with relapsed Hodgkin’s lymphoma
by: N. A. Avxentyev, et al.
Published: (2020-12-01)

Safe prolonged use of brentuximab vedotin in a patient with Classical Hodgkin Lymphoma on hemodialysis
by: Aimee Schad, et al.
Published: (2023-09-01)

Primary Cutaneous CD30-Positive Lymphoproliferative Disorders—Current Therapeutic Approaches with a Focus on Brentuximab Vedotin
by: Tomasz Stein, et al.
Published: (2024-01-01)

Combining BeEAM with Brentuximab Vedotin for High-Dose Therapy in CD30 Positive Lymphomas before Autologous Transplantation—A Phase I Study
by: Christian Rausch, et al.
Published: (2022-09-01)

Brentuximab vedotin in children and adolescents with Hodgkin’s lymphoma and anaplastic large cell lymphoma – literature review and own experience
by: N. V. Myakova, et al.
Published: (2016-03-01)

Assessment of the efficiency of Brentuximab Vedotin in patients with pulmonary Hodgkin Lymphoma by the mean of neutrophil to lymphocyte ratio
by: Gokhan Erdem, et al.
Published: (2018-04-01)

P072 (0038) FRONTLINE BRENTUXIMAB VEDOTIN PLUS CHEMOTHERAPY EXHIBITS SUPERIOR MODIFIED PROGRESSION-FREE SURVIVAL VS CHEMOTHERAPY ALONE IN PATIENTS WITH STAGE III OR IV HODGKIN LYMPHOMA: PHASE 3 ECHELON-1 STUDY
Published: (2018-10-01)

P139 (0169) BRENTUXIMAB VEDOTIN ALONE AND IN COMBINATION WITH BENDAMUSTINE AS SALVAGE THERAPY FOR PRIMARY REFRACTORY OR RELAPSED HODGKIN LYMPHOMA: MULTICENTRE EXPERIENCE OF THE POLISH LYMPHOMA RESEARCH GROUP
Published: (2018-10-01)

T015 (0124) BRENTUXIMAB VEDOTIN AND AVD CHEMOTHERAPY FOLLOWED BY REDUCED DOSE/VOLUME RADIOTHERAPY IN PATIENTS WITH EARLY STAGE, UNFAVORABLE HODGKIN LYMPHOMA
Published: (2018-10-01)

Results of a multicentre UK-wide retrospective study evaluating the efficacy of brentuximab vedotin in relapsed, refractory classical Hodgkin lymphoma in the transplant naive setting
by: Eyre, T, et al.
Published: (2017)

The role of radiotherapy in patients with refractory Hodgkin's lymphoma after treatment with brentuximab vedotin and/or immune checkpoint inhibitors
by: Ruizhi Zhao, et al.
Published: (2024-03-01)

P111: Phase I Trial of Brentuximab Vedotin plus Cyclosporine in Relapsed/Refractory Hodgkin Lymphoma
by: Swetha Kambhampati, et al.
Published: (2022-10-01)

P112: Phase II Trial of Brentuximab Vedotin plus ibrutinib in Relapsed/Refractory Hodgkin Lymphoma
by: Matthew Mei, et al.
Published: (2022-10-01)

Potentials of brentuximab vedotin in the treatment of relapse/refractory cutaneous T-cell lymphomas: literature review and authors’ observation
by: L. G. Gorenkova, et al.
Published: (2019-07-01)

Efficacy of brentuximab vedotin in patients with CD30-positive lymphoproliferative skin diseases: results of the first prospective study in the Russian Federation
by: Irena E. Belousova, et al.
Published: (2022-05-01)

P071 (0024) A MULTICENTER PHASE 2 STUDY OF SEQUENTIAL BRENTUXIMAB VEDOTIN AND AVD CHEMOTHERAPY FOR OLDER PATIENTS WITH UNTREATED CLASSICAL HODGKIN LYMPHOMA
Published: (2018-10-01)

T087: Brentuximab vedotin (Bv) Demonstrates Superior Event-Free Survival in Pediatric High-Risk Hodgkin Lymphoma
by: Sharon M. Castellino, et al.
Published: (2022-10-01)